Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.
Malaguarnera, Michele, Gargante, Maria Pia, Cristaldi, Erika et al. · Archives of gerontology and geriatrics · 2008 · DOI
Quick Summary
Researchers tested whether a supplement called acetyl L-carnitine (ALC) could help reduce fatigue in older adults (over 70 years old) who met criteria for chronic fatigue syndrome. After treatment, patients showed meaningful improvements in physical tiredness, mental fatigue, sleep problems, and thinking ability. The supplement appeared to be safe and well-tolerated.
Why It Matters
ME/CFS patients frequently report severe fatigue and cognitive impairment with limited effective pharmacological options. If replicated, ALC could represent a relatively safe, well-tolerated adjunctive intervention for symptom management in an aging ME/CFS population, particularly for post-exertional malaise and cognitive dysfunction.
Observed Findings
Physical fatigue decreased by 6.2 points in the treatment group versus −0.5 in controls (p<0.0001)
Post-exertional fatigue (prolonged fatigue after exercise) improved by 51% in the ALC group versus −4% in controls (p<0.0001)
Muscle pain decreased by 27% with ALC treatment versus only 3% in controls (p<0.05)
Mini-Mental State Examination scores improved by 3.4 points with ALC versus 0.5 points in controls (p<0.0001)
Functional status improved by 17.1 points in the treatment group versus 0.6 in controls (p<0.0001)
Inferred Conclusions
Acetyl L-carnitine reduces both physical and mental fatigue in elderly patients with chronic fatigue syndrome
ALC improves cognitive function and activities of daily living in this population
ALC may be particularly effective for post-exertional malaise and sleep disturbances
The supplement appears tolerable with no reported serious adverse effects in elderly subjects
Remaining Questions
What is the optimal dose and duration of ALC treatment, and are there age-dependent dosing considerations?
What This Study Does Not Prove
This study does not establish whether ALC works in younger ME/CFS populations or in non-elderly subgroups with different disease severity. It does not clarify the biological mechanism of benefit, nor does it prove ALC is superior to other carnitine formulations or established non-pharmacological interventions. The lack of detailed protocol and outcome specification in the abstract limits assessment of potential bias.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does ALC benefit remain sustained after treatment discontinuation, or is ongoing supplementation required?
What is the mechanism by which ALC alleviates fatigue and improves cognition in ME/CFS—mitochondrial function, carnitine deficiency repletion, or other pathways?
Does ALC efficacy differ based on ME/CFS severity, disease duration, or presence of comorbidities?